A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
-
ACADEMIA Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
-
REGULATORY Average Price Gap for FY2022 Revision Likely to Be 8% Level or Lower: Wholesalers
October 20, 2021
-
COMMENTARY LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
October 19, 2021
-
BUSINESS Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
-
BUSINESS Alfresa to Introduce Digital-Driven Deliveries at All Offices by August 2024; Test Run Showing Good Results
October 18, 2021
-
COMMENTARY Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
October 15, 2021
-
ORGANIZATION Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
-
ORGANIZATION EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
-
COMMENTARY Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
October 13, 2021
-
BUSINESS Japan Drug Makers Prepping to Launch New Organization to Solve Challenges in Digital Health
October 13, 2021
-
REGULATORY Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
-
BUSINESS Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
-
BUSINESS Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
-
REGULATORY MHLW Orders Large-Scale Carcinogen Risk Inspections, Covering Almost All Drugs
October 11, 2021
-
REGULATORY Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
-
REGULATORY Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
-
BUSINESS Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
-
ORGANIZATION JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
-
BUSINESS Takeda Suspends PII Trials of Narcolepsy Drug Hopeful on Safety Concerns
October 7, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…